• Adalta Limited (ASX:1AD) has lodged a prospectus with ASIC for an offer of options.
• The offer is made to sophisticated and professional investors.
• The offer is in connection with a previously announced placement.
• An extraordinary general meeting is scheduled to seek shareholder approval.

Adalta Limited (ASX:1AD) has lodged a prospectus with ASIC for an offer of options to be issued in connection with a placement previously announced on May 4, 2026. The offer is made to sophisticated and professional investors who have participated in the placement. The prospectus outlines the terms of the offer and the opportunity for investors to apply for one attaching New Option for every three New Shares subscribed for under the placement. The offer is subject to shareholder approval, which will be sought through an extraordinary general meeting scheduled for June 15, 2026.

Adalta Limited aims to raise approximately up to $2.5 million before issue costs through the placement.

Adalta Ltd is focused on developing next-generation cellular immunotherapies for solid cancers, with a specific focus on mesothelioma and other cancers.